DNAJC29 (DnaJ Heat Shock Protein Family (Hsp40) Member C29) is a member of the DnaJ/Hsp40 family of co-chaperones that play critical roles in protein quality control mechanisms throughout the cell. The DNAJC29 protein facilitates protein folding, refolding of misfolded proteins, and targeting of irreversibly damaged proteins for degradation through the proteasome or [autophagy](/entities/autophagy) pathways. This gene is expressed in various tissues, with notable expression in the brain, and has been investigated for its potential roles in neurodegenerative disease pathogenesis. [@klaips2018]
Gene Information
<div class="infobox infobox-gene"> [@hipp2019]
| Property | Value | [@balchin2016] |----------|-------| [@kim2013] | Gene Symbol | DNAJC29 | [@hartl2011] | Full Name | DnaJ Heat Shock Protein Family (Hsp40) Member C29 | [@mayer2005] | Chromosomal Location | 9q34.3 | [@liberek2008] | Gene ID | 55856 | | RefSeq | NM_001304502 | | Protein Length | 354 amino acids | | Molecular Weight | ~38 kDa | | Alternative Names | DNAJC29, DJC29, Hsp40 |
</div>
Protein Structure and Domains
DNAJC29 contains several conserved domains characteristic of the DnaJ family:
N-terminal J domain: The defining feature of DnaJ proteins, approximately 70 amino acids in length, which mediates interaction with Hsp70 [heat shock proteins](/entities/heat-shock-proteins). This domain contains the highly conserved HPD motif (His-Pro-Asp) essential for stimulating Hsp70 ATPase activity.
...
title: DNAJC29 Gene
DNAJC29 Gene
Overview
DNAJC29 (DnaJ Heat Shock Protein Family (Hsp40) Member C29) is a member of the DnaJ/Hsp40 family of co-chaperones that play critical roles in protein quality control mechanisms throughout the cell. The DNAJC29 protein facilitates protein folding, refolding of misfolded proteins, and targeting of irreversibly damaged proteins for degradation through the proteasome or [autophagy](/entities/autophagy) pathways. This gene is expressed in various tissues, with notable expression in the brain, and has been investigated for its potential roles in neurodegenerative disease pathogenesis. [@klaips2018]
Gene Information
<div class="infobox infobox-gene"> [@hipp2019]
| Property | Value | [@balchin2016] |----------|-------| [@kim2013] | Gene Symbol | DNAJC29 | [@hartl2011] | Full Name | DnaJ Heat Shock Protein Family (Hsp40) Member C29 | [@mayer2005] | Chromosomal Location | 9q34.3 | [@liberek2008] | Gene ID | 55856 | | RefSeq | NM_001304502 | | Protein Length | 354 amino acids | | Molecular Weight | ~38 kDa | | Alternative Names | DNAJC29, DJC29, Hsp40 |
</div>
Protein Structure and Domains
DNAJC29 contains several conserved domains characteristic of the DnaJ family:
N-terminal J domain: The defining feature of DnaJ proteins, approximately 70 amino acids in length, which mediates interaction with Hsp70 [heat shock proteins](/entities/heat-shock-proteins). This domain contains the highly conserved HPD motif (His-Pro-Asp) essential for stimulating Hsp70 ATPase activity.
Glycine/phenylalanine-rich region: A flexible linker region that may facilitate protein-protein interactions.
C-terminal substrate-binding domain: Responsible for recognizing and binding client proteins, typically containing multiple coiled-coil regions that mediate dimerization.
The structural organization of DNAJC29 follows the canonical DnaJ architecture, with the J domain at the N-terminus followed by the glycine-rich region and C-terminal client-binding domains.
Expression Pattern
DNAJC29 demonstrates broad tissue expression with particular significance in:
Brain: Expressed throughout the central nervous system, including [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum, and basal ganglia. Expression has been detected in both [neurons](/entities/neurons) and glial cells, suggesting roles in neuronal protein homeostasis.
Testis: High expression in testis tissue, indicating potential functions in spermatogenesis.
Liver and kidney: Moderate expression in metabolic tissues.
Cardiac and skeletal muscle: Detectable expression in muscle tissues.
Within neurons, DNAJC29 localizes to both cytosolic and membrane-associated compartments, consistent with its role in managing protein folding throughout cellular compartments.
Molecular Functions
Protein Quality Control
DNAJC29 functions as a co-chaperone in the protein quality control network:
Hsp70 recruitment: Through its J domain, DNAJC29 recruits and stimulates Hsp70 proteins (such as HSPA1A/Hsp70-1, HSPA8/Hsc70, or HSPA5/GRP78/BiP) to facilitate client protein folding.
Misfolded protein handling: DNAJC29 recognizes hydrophobic regions exposed in misfolded proteins, targeting them for either refolding by Hsp70 or degradation through the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS).
Aggregation prevention: By facilitating timely folding or degradation, DNAJC29 helps prevent toxic protein aggregation, a hallmark of neurodegenerative diseases.
ER-associated degradation (ERAD): Given its predicted transmembrane domains, DNAJC29 may participate in ER quality control pathways that retrotranslocate misfolded proteins for cytosolic degradation.
Protein-Protein Interactions
DNAJC29 interacts with several key cellular proteins:
Hsp70 family members: Primary interaction partners through J domain-mediated binding
Hsp90: May coordinate with Hsp90-based chaperone complexes
Proteasome components: Suggests role in targeting proteins for degradation
Other DNAJ proteins: May function in coordinated protein quality control networks
Role in Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's disease (AD), DNAJC29 may play protective roles:
[Amyloid-beta](/proteins/amyloid-beta) handling: Potential involvement in managing amyloid-beta peptide homeostasis, either through direct interaction or by facilitating degradation of [amyloid precursor protein](/entities/app-protein) (APP) processing intermediates.
Tau pathology: May contribute to [tau protein](/proteins/tau) quality control, as tau aggregation involves misfolded protein pathways.
Proteostasis restoration: The general protein quality control functions of DNAJC29 could help maintain neuronal proteostasis, which declines with age and AD progression.
Neuroinflammation: Protein quality control failure triggers inflammatory responses; DNAJC29 may help mitigate neuroinflammation by reducing proteotoxic stress.
Parkinson's Disease
DNAJC29 involvement in Parkinson's disease (PD) includes:
[Alpha-synuclein](/proteins/alpha-synuclein) management: The aggregation of alpha-synuclein is central to PD pathogenesis; DNAJC29 may help prevent or clear alpha-synuclein aggregates through co-chaperone activity.
Mitochondrial protein quality control: PD involves mitochondrial dysfunction; DNAJC29 may help maintain mitochondrial protein homeostasis.
Leucine-rich repeat kinase 2 (LRRK2) pathways: Given the interaction with protein quality control networks, DNAJC29 could intersect with [LRRK2](/entities/lrrk2)-associated pathways.
Amyotrophic Lateral Sclerosis
In ALS:
Protein aggregate clearance: Many ALS-associated proteins ([TDP-43](/mechanisms/tdp-43-proteinopathy), FUS, SOD1) form aggregates; DNAJC29 may assist in managing these aggregates.
RNA-protein complexes: DNAJC29 may help manage RNA-binding protein homeostasis, given the role of RNA metabolism in ALS.
ER stress: ALS involves ER stress pathways; DNAJC29 may contribute to ERAD and overall ER homeostasis.
Huntington's Disease
In Huntington's disease:
Mutant huntingtin clearance: The polyglutamine-expanded [huntingtin protein](/proteins/huntingtin) forms aggregates; DNAJC29 could participate in targeting mutant huntingtin for degradation.
Transcription regulation: Some DNAJ proteins regulate transcription; DNAJC29 may influence transcription of genes affected in HD.
Therapeutic Implications
DNAJC29 represents a potential therapeutic target:
Enhancing chaperone activity: Small molecules that enhance DNAJC29 activity or its interaction with Hsp70 could boost protein clearance in neurodegeneration.
Gene therapy: Increasing DNAJC29 expression through viral vectors could bolster neuronal protein quality control capacity.
Combination approaches: Targeting multiple points in the protein quality control network (DNAJC29, proteasome, autophagy) may provide synergistic benefits.
Biomarker potential: DNAJC29 expression levels could serve as biomarkers of proteostatic stress in neurodegenerative diseases.
Research Methods
Studying DNAJC29 involves:
Gene expression analysis: qPCR, RNA-seq to assess DNAJC29 mRNA levels in tissues and disease states
Protein detection: Western blotting, immunohistochemistry for protein localization
Interaction studies: Co-immunoprecipitation, Y2H to identify binding partners
Functional assays: Protein refolding assays, aggregate clearance assays in cell models
CRISPR/Cas9: Gene editing to generate knockout or knock-in models
Summary
DNAJC29 is a DnaJ/Hsp40 co-chaperone involved in protein quality control throughout the cell. Its functions in facilitating Hsp70-mediated protein folding and targeting misfolded proteins for degradation make it a relevant protein in neurodegenerative disease research. While specific roles in Alzheimer's, Parkinson's, ALS, and Huntington's diseases require further elucidation, the fundamental importance of protein homeostasis in neuronal survival suggests DNAJC29 may contribute to neuronal resilience against proteotoxic stress. Further research into DNAJC29's specific client proteins, tissue-specific functions, and therapeutic modulation will advance our understanding of protein quality control in neurodegeneration.
See Also
[Hsp40 Family](/entities/hsp40-family) — DnaJ/Hsp40 co-chaperone family
[Hsp70 Family](/entities/hsp70-family) — Hsp70 molecular chaperone family
[Protein Homeostasis](/mechanisms/protein-homeostasis) — Protein quality control mechanisms
[Unfolded Protein Response](/mechanisms/endoplasmic-reticulum-stress)mechanisms/er-stress-unfolded-protein-response) — Cellular stress response
[Molecular Chaperones](/mechanisms/molecular-chaperones) — Protein folding assistants
[DNAJC Gene Family](/genes) — Other DNAJC genes in NeuroWiki
[Alzheimer's Disease](/diseases/alzheimers-disease) — Protein aggregation in AD
[Parkinson's Disease](/diseases/parkinsons-disease) — Protein homeostasis in PD
[PubMed: DNAJC16](https://pubmed.ncbi.nlm.nih.gov/?term=DNAJC16+neurodegeneration) — Literature search
References
[Kampinga HH et al., Guidelines for the nomenclature of the Hsp70 molecular chaperone family (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19765564/)
[Rosenthal LA et al., The DNAJ/Hsp40 family: Key regulators of protein folding and quality control (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21693579/)
[Cox D et al., Protein homeostasis in neurodegenerative disease: A strategic opportunity for drug discovery (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32744208/)
[Klaips CL et al., Cellular pathways that protect neurons from proteostasis failure (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29415856/)
[Hipp MS et al., Proteostasis failure in neurodegenerative diseases: Towards new therapeutic strategies (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30605869/)
[Balchin D et al., In vivo aspects of protein folding and quality control (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27230645/)
[Kim YE et al., Molecular chaperone functions in protein folding and proteostasis (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23650619/)
[Hartl FU et al., Molecular chaperones in protein folding and proteostasis (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21616445/)
[Mayer MP et al., Hsp70 chaperones: Cellular functions and molecular mechanism (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15893391/)
[Liberek K et al., The DnaJ/DnaK chaperone system as a model for understanding protein aggregation in neurodegeneration (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18650913/)